Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599210 | 0.88 | CYP1A2 (0.48) | CYP1A2CYP2A6KDM1AALOX5F2 | |
| SCHEMBL3258851 | 0.74 | CYP1A2 (0.41) | CYP1A2CYP2A6TSHR | |
| SCHEMBL3165311 | 0.73 | CYP1A2 (0.40) | CYP1A2CYP2A6TSHR | |
| SCHEMBL14382043 | 0.71 | CYP1A2 (0.38) | CYP1A2CYP2A6TSHR | |
| SCHEMBL3160246 | 0.71 | CYP1A2 (0.47) | CYP1A2CYP2A6TSHR | |
| SCHEMBL7659214 | 0.71 | CYP1A2 (0.47) | CYP1A2CYP2A6TSHRGRIN2B | |
| SCHEMBL3161110 | 0.71 | CYP1A2 (0.47) | CYP1A2CYP2A6TSHR | |
| SCHEMBL7729685 | 0.70 | MAOB (0.39) | TSHRALOX5APFEN1MAOBRXRA | |
| SCHEMBL14866808 | 0.70 | ALDH1A1 (0.38) | TSHR | |
| SCHEMBL3157940 | 0.70 | CYP1A2 (0.37) | CYP1A2CYP2A6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581469-B1 | METHOD FOR PRODUCING 2,6-SUBSTITUTED TRANS DECALIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-7276633-B2 | Method for production naphthalene derivatives | MERCK PATENT GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20060025615-A1 | Method for production naphthalene derivatives | MERCK PATENT GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| EP-1581469-A1 | METHOD FOR PRODUCING NAPHTHALENE DERIVATIVES | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004050594-A1 | METHOD FOR PRODUCING NAPHTHALENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025615-A1 | Method for production naphthalene derivatives | AOX1, AOC3, CBR3 | CYP1A2 270/4885CYP2A6 646/4885MRGPRX4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.